Scarica l'app Stockscreener
2.85
3.39%
-0.10
Precedente Chiudi:
$2.95
Aprire:
$2.86
Volume 24 ore:
23,080
Relative Volume:
1.98
Capitalizzazione di mercato:
$41.32M
Reddito:
-
Utile/perdita netta:
$-16.26M
Rapporto P/E:
-1.2605
EPS:
-2.261
Flusso di cassa netto:
$-13.50M
1 W Prestazione:
-10.24%
1M Prestazione:
-14.41%
6M Prestazione:
-41.12%
1 anno Prestazione:
+30.48%
Intervallo 1D:
$2.76
$2.95
Intervallo di 1 settimana:
$2.76
$3.2999
Portata 52W:
$2.1446
$11.44
Intensity Therapeutics Inc Stock (INTS) Company Profile
Nome
Intensity Therapeutics Inc
Settore
Industria
Telefono
203-221-7381
Indirizzo
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Confronta INTS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| INTS | 2.86 | 41.32M | 0 | -16.26M | -13.50M | -2.261 |
| VRTX | 446.61 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.00 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.85 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Intensity Therapeutics Inc Borsa (INTS) Ultime notizie
Intensity Therapeutics secures $3 million in stock offering - Investing.com
Intensity Therapeutics Raises $3M Through Stock Offering & Warrant Placement | INTS Stock News - StockTitan
Intensity reports promising sarcoma treatment results - Investing.com
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at - StreetInsider.com
Intensity Therapeutics' Cancer Drug Triples Survival Time in Phase 1/2 Sarcoma Trial | INTS Stock News - StockTitan
Q&A: New cancer medication to treat refractory solid tumours - Digital Journal
Intensity Therapeutics Reports Wider Q3 Loss, Advances Key Cancer Drug Trials | INTS Stock News - StockTitan
3 US Penny Stocks With Market Caps Under $200M To Watch - Simply Wall St
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting - The Malaysian Reserve
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - Quantisnow
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - The Manila Times
TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire
INTSIntensity Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Balancing Decisions Around Breast Cancer Treatment and Fertility, Breastfeeding - Curetoday.com
New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy - Yahoo Finance
Intensity Therapeutics grants stock options to top executives By Investing.com - Investing.com South Africa
Intensity Therapeutics grants stock options to top executives - Investing.com
High-intensity, low-impact training (HILIT) is gentle on joints and can boost your metabolism. Here’s how to get started - Yahoo Finance
Biliary Tumor Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
SONIRE’s HIFU Therapy System Designated as Breakthrough Device by FDA - BioSpace
SONIRE's HIFU Therapy System Designated as Breakthrough Device by FDA - The Manila Times
Cholangiocarcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Thoracic Re-irradiation With Definitive External Beam Radiation Therapy Using Intensity Modulated Radiation Therapy: A Case Report - Cureus
Herceptin, Perjeta Regimen May Be Effective Without Chemo in Breast Cancer - Curetoday.com
Side Effects, Quality of Life Important to Consider in Breast Cancer Subset - Curetoday.com
There is Nothing Pink About Breast Cancer - Curetoday.com
Head and Neck Cancer Therapeutics Market Overview: Breakthrough Treatments, Technological Innovations, and ... - WhaTech
An Analysis of Ideaya Biosciences Inc (IDYA)’s Potential Price Growth - Knox Daily
Weekly Investment Analysts’ Ratings Changes for Incyte (INCY) - Defense World
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
InvenTrust Properties (NYSE:IVT) Sees Strong Trading Volume - Defense World
Skandinaviska Enskilda Banken AB publ Increases Position in Itron, Inc. (NASDAQ:ITRI) - Defense World
Ideaya Biosciences price target lowered to $52 from $54 at Wedbush - TipRanks
Hoosier Hysterics Podcast: Sisley commits, plus IUWBBs Shay Ciezki and Karoline Striplin - 247Sports
Ideaya Biosciences should be bought on weakness, says Citi - TipRanks
Intapp, Inc. (NASDAQ:INTA) Shares Sold by Hood River Capital Management LLC - MarketBeat
(TIL) Long Term Investment Analysis - Stock Traders Daily
Low-intensity pulsed ultrasound modulates disease progression in the SOD1 - ScienceDirect.com
Itim Group PLC Announces Strong Mid-Year Financials - TipRanks
ITT Educational Services (OTCMKTS:ESINQ) Stock Price Passes Above Two Hundred Day Moving Average of $0.00 - Defense World
InvenTrust Properties Corp. Announces Upsizing and Pricing of Common Stock Offering - StockTitan
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Intense Technologies Limited's (NSE:INTENTECH) CEO For Now - Simply Wall St
US FDA Closes Out Problem Applications One Federal Register Notice At A Time - Pink Sheet
Ideaya Biosciences price target lowered to $66 from $68 at Stifel - TipRanks
BTIG maintains $62 target on Ideaya Biosciences stock - Investing.com
From Statins to PSCK9 Inhibitors: Choosing the Right Therapy for Cholesterol - Pharmacy Times
Intercontinental Exchange, Inc. (NYSE:ICE) Shares Sold by Interval Partners LP - Defense World
ILLIT Comeback 'I'll Like You' Mini-Album: Release Date, Tracklist - J-14
Integra Lifesciences Holdings Corp (IART) Becoming More Attractive for Investors - Knox Daily
Itau Unibanco Holding S.A. Acquires New Position in Incyte Co. (NASDAQ:INCY) - Defense World
Intensity Therapeutics Inc Azioni (INTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):